Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate an oral fixed-dose, once daily product that combines pramipexole and
rasagiline for the treatment of early Parkinson's disease.
Animal studies support the therapeutic advantage of combining low doses of rasagiline and
pramipexole and suggest further improvement when both are administered in a sustained
fashion. Both rasagiline and pramipexole are well known marketed drugs for Parkinson's
disease with a good safety profile. combining the drugs in low doses and controlled release
may provide better symptom management than the existing drugs alone or together.